ECHOPULSE

About Theraclion

Theraclion's mission is to disrupt invasive surgery through its proprietary robotic HIFU (echotherapy) platform, enabling precise, non-invasive tissue ablation. The company has achieved commercial traction with its SONOVEIN system for varicose veins, supported by CE Mark and FDA-pivotal trial data, and is expanding its geographic footprint. Its strategy focuses on dominating the non-invasive venous treatment segment while leveraging its adaptable platform for future indications in oncology and beyond.

About Theraclion

Theraclion's mission is to disrupt invasive surgery through its proprietary robotic HIFU (echotherapy) platform, enabling precise, non-invasive tissue ablation. The company has achieved commercial traction with its SONOVEIN system for varicose veins, supported by CE Mark and FDA-pivotal trial data, and is expanding its geographic footprint. Its strategy focuses on dominating the non-invasive venous treatment segment while leveraging its adaptable platform for future indications in oncology and beyond.

Therapeutic Areas